EU stands firm on biosimilar naming as WHO pursues qualifier plan
This article was originally published in Scrip
Executive Summary
As arguments continue to rage over whether biosimilars should carry the same non-proprietary name as their reference drug, a global naming system for biosimilars seems as far away as ever, at least to judge by recent moves in this area by key regulatory and health authorities across the world.